Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.05. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
CREATIVE MEDICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
06.05. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
25.04. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
04.04. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
02.04. | Creative Medical Technology files to sell 1.8M shares of common stock by selling shareholders | 2 | Seeking Alpha | ||
20.03. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain | 69 | GlobeNewswire (Europe) | PHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (the "Company"), a clinical-stage biotechnology company specializing in regenerative medicine... ► Artikel lesen | |
19.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
14.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
14.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
07.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
06.03. | Creative Medical Technology sichert sich 3,7 Millionen US-Dollar durch Optionsscheine | 6 | Investing.com Deutsch | ||
06.03. | Creative Medical Technology secures $3.7 million through warrants | 1 | Investing.com | ||
06.03. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds | 1 | GlobeNewswire (USA) | ||
14.02. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine ... | 126 | GlobeNewswire (Europe) | PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a pioneering biotechnology firm specializing... ► Artikel lesen | |
11.02. | Creative Medical reports progress in Type 2 Diabetes treatment | 1 | Investing.com | ||
11.02. | Creative Medical meldet Fortschritte bei der Behandlung von Typ-2-Diabetes | 1 | Investing.com Deutsch | ||
11.02. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Reports Positive One-Year Results for AlloStem Type 2 Diabetes Program | 132 | GlobeNewswire (Europe) | PHOENIX, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced... ► Artikel lesen | |
05.02. | Creative Medical Technology Holdings (CELZ): AI-Enhanced Stem Cell Therapy for Diabetes | 2 | Insider Monkey | ||
05.02. | Creative Medical verbessert Diabetesbehandlung mit KI-Technologie | 3 | Investing.com Deutsch | ||
05.02. | Creative Medical enhances diabetes treatment with AI tech | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,280 | -0,11 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
BIONTECH | 96,45 | +0,21 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen | |
EVOTEC | 6,994 | -2,10 % | Ihre wichtigsten Termine: Spannende Updates von: General Motors, British American Tobacco, Evotec & Adesso | © Foto: Marijan Murat - dpa-BildfunkGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,790 | +0,17 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,575 | 0,00 % | Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? | ||
KYMERA THERAPEUTICS | 47,670 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
ENLIVEN THERAPEUTICS | 21,370 | -4,13 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
VERA THERAPEUTICS | 30,570 | 0,00 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 19,720 | 0,00 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
APOGEE THERAPEUTICS | 37,660 | +3,18 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 29,530 | 0,00 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen | |
VERVE THERAPEUTICS | 5,725 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 48,870 | 0,00 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
MODERNA | 23,550 | -3,50 % | Allianz, Amazon, Deutsche Konsum, Gerresheimer, Hensoldt, Moderna - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CULLINAN THERAPEUTICS | 8,740 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases | Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with... ► Artikel lesen |